Listen to The Lancet

<p>Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH...

<p>Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax...

<p>Ultra-processed foods are on the rise. Despite the emphasis placed on individual responsibility, our deteriorating diets are primarily the result of the sophisticated political tactics of a powerful global...

<p>Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO...

<p>Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.</p>

<p>Walter Willett, Shakuntala Thilsted and Johan Rockström discuss the second EAT-Lancet Commission report.</p>

<p>Stephen Chan joins Ben Abbott of The Lancet to discuss the key messages of the Lancet Commission on addressing the global hepatocellular carcinoma burden, which is published today on World Hepatitis Day.</p>

<p>Rebecca Fitzgerald joins us to discuss her recent prospective real-world implementation study of capsule sponge risk stratification in Barrett’s oesophagus surveillance in the UK.</p>

<p>Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously...

<p>Francis Couturaud joins Chloe Wilson of The Lancet to discuss the RENOVE trial, which looks at assessing the efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom...

<p>Donald Trump has taken office in the US and immediately turned his attention to dismantling the US position as a world leader in global health. How will actions taken so far affect the health of people around the...

<p>Michael Heneka joins Chloe Wilson and Bea Gomez Perez-Nievas of The Lancet to discuss a therapeutics paper discussing the opportunities and challenges of passive anti-amyloid β immunotherapy in Alzheimer's...

<p>ROSHNI-2 was a multicentre, randomised controlled trial that investigated the efficacy of a culturally adapted, cognitive behavioural therapy-based intervention for postnatal depression in British south Asian women...

<p>Rasha Al-Lamee and Shayna Chotai join Chloe Wilson of The Lancet to discuss ESC Congress 2024 highlights.</p>

<p>Gavin is joined by Paul Moran and Helen Christensen to discuss The Lancet's new commission on self-harm, exploring its prevalence, cultural factors, and the crucial need for better data and compassionate care. We...